Omeros, Anavex Results Positive, Protagonist Suffers Setback: The Good, Bad, And Ugly Of Biopharma [Seeking Alpha]
Anavex Life Sciences Corp. (AVXL)
NASDAQ:AMEX Investor Relations:
anavex.com/share-data
Company Research
Source: Seeking Alpha
Omeros, Anavex Results Positive, Protagonist Suffers Setback: The Good, Bad, And Ugly Of Biopharma Summary OMS721 showed positive data in pivotal study; however, now, we also have a secondary offering. Anavex came up with positive phase 2a extension data. Investors seem disappointed with Protagonist data. Omeros (NASDAQ: OMER assessments Primary efficacy endpoint Secondary endpoints There were other improvements in various metrics like platelet count, LDH, haptoglobin, improvements in hemoglobin and creatinine across all groups as well as across complete responders. Safety signals were good. There were no treatment-related deaths; in the phase 2 trial, there was one death out of 9 total deaths which could not be ruled out as not being treatment-related. Earlier this year, we wrote a bullish article on OMER; this followed a set of articles we wrote in the years before that. Omeros has an approved drug called OMIDRIA which is generating a stream of revenue; however, OMS721 has always
Show less
Read more
Impact Snapshot
Event Time:
AVXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVXL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVXL alerts
High impacting Anavex Life Sciences Corp. news events
Weekly update
A roundup of the hottest topics
AVXL
News
- Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Anavex Life Sciences Announces Expansion of Leadership Team [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences Announces Expansion of Leadership TeamGlobeNewswire
- Anavex Life Sciences (NASDAQ:AVXL) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Lifshitz Law PLLC Announces Investigations of Anavex Life Sciences Corporation (NASDAQ:AVXL), Innoviz Technologies Ltd. (NASDAQ:INVZ), agilon health, inc. (NYSE:AGL), and The Chemours Company (NYSE:CC)Accesswire
AVXL
Earnings
- 5/9/24 - In-Line
AVXL
Sec Filings
- 5/17/24 - Form 4
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- AVXL's page on the SEC website